Oncotarget Provide Deep understanding of Oncology Research

Oncotarget is one of the major medical journals that has produced many papers on oncology. It was established in 2010 with an intention to provide information on existing and new ways of treating and preventing cancer. Oncology is the study of the prevention and diagnosis of disease. Oncotarget research focuses on this area of medical treatment and is produced on a weekly basis. You can get a free soft copy online, or you can order a printed copy from the publisher.

Oncotarget has made it easier for people to access information about oncology. The discoveries on oncology and cancer biology are shared among many people around the world to help propagate scientific discovery and awareness.

It increases the impacts of research because many scholars can access the information that will help them to conduct further research on the same issues. Doing so expands the number of topics to be covered including cell biology, aging, endocrinology, and neuroscience. Oncotarget touches on several topics to help develop collaboration between the scholars from different medical disciplines and eliminates the differences between them. Follow Oncotarget on Twitter.

Oncology had a great impact factor averaging 5.4 over the past seven years. This means that Oncotarget papers are among the top peer-reviewed journal articles by researcher all over the world. It has been ranked highly by Scopus in the discipline of oncology and medicine in general ever since 2011. Oncotarget researchers include distinguished researchers and scientists who are also the editors of independent journals. The editorial team includes some of the top prize winners in the medical field too. It is the efforts of the competent researchers and scientists that have made Oncotarget to be the internationally acclaimed entity that it is today. Learn more about Oncotarget at Eurekalert.org.

There are several key ways that Oncotarget has improved research in the field of oncology. It crosses bridges and allows scientific evidence to be presented from a wide spectrum of disciplines. It also tailors information that is the most relevant to the scientific community. This unique perspective helps create a system of growth and collaboration due to the clear and timely publication of important findings and research.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Dr. Clay Siegall Enhances The Success Of Seattle Genetics

Dr. Clay Siegall is a renowned scientist. He is credited for making positive contributions in the industry, including propelling research in field of cancer therapy. He is the CEO of Seattle Genetics, a biotech firm that specializes in the development and commercialization of antibody-based therapies for cancer and other chronic diseases. Through his transformative leadership, the company has been able to register notable achievements, including the approval of their first antibody drug conjugate-ADC, Adcetris by FDA in 2011. Moreover, he has pushed for the commercialization of Adcetris by entering into multiple partnerships.

Speaking to Inspirery, the visionary leader said that was inspired to venture into genetics after seeing a family member suffer from cancer treatment. Driven by the desire to create alternative treatments that would cause less harm to patients, he advanced his studies in genetics before co-founding Seattle Genetics. The successful company makes money from the sale of their own drugs. In addition, substantial revenues are sourced from its production collaborations. The company also makes money from licenses arising from Seattle Genetics’ technologies.

About Clay Siegall

Dr. Clay Siegall holds a BS in zoology and a PhD in genetics from the renowned University of Maryland and George Washington University respectively. His visionary leadership at Seattle Genetics has seen the biotechnology firm rise to greater heights in the industry. Under his leadership, the company has set a track record of developing the most innovative therapies that are based on rigorous research. Apart from the development and commercialization of Adcetris, Seattle Genetics has embarked on a pipeline development of more than 20 drugs. In addition, the company has entered into partnerships with other drug manufacturers like Genentech and Bayer.

Before starting his journey with Seattle Genetics, Clay Siegall had rendered his services in various companies, including the Bristol-Myers Squibb Pharmaceutical Research Institute, National Institute of Health and the National Cancer institute. Presently, he serves on the boards of Alder BioPharmaceuticals, the Washington Roundtable, Ultragenyx Pharmaceutical and Mirna Therapeutics. In 2013, the University of Maryland recognized Dr. Clay as the Alumnus of the Year for Computer, Math and Natural Sciences. The celebrated scientist has authored over 70 publications and holds 15 patents.